Psychiatry & Mental Health

Choosing the Right Antidepressant Just Got a Little Easier: What NPs Need to Know About the PETRUSHKA Trial

A new decision-support tool helped patients stay on their antidepressant longer and feel better at six months. Here's what it means for your prescribing practice.

If you've ever stared at a list of SSRIs and SNRIs wondering which one will actually work for the patient sitting across from you, you're not alone. The antidepressant selection process has long been described as "educated trial and error," and for good reason—we've had limited tools to meaningfully guide that first-line choice. A large new randomized trial published in JAMA in March 2026 offers some encouraging evidence that a structured, personalized approach can improve outcomes.

The Study at a Glance

Cipriani and colleagues conducted a multicenter RCT across 47 sites in Brazil, Canada, and the UK, enrolling 540 adults aged 18–74 with major depressive disorder. Participants were randomized 1:1 to either a clinical decision-support system called the PETRUSHKA tool or usual care. The tool is web-based and uses a combination of clinical and demographic predictors alongside patient preferences to recommend a specific antidepressant.

The primary outcome was straightforward and clinically relevant: treatment discontinuation due to any cause at 8 weeks. Secondary outcomes included discontinuation due to adverse events, plus changes in depressive symptoms (PHQ-9) and anxiety symptoms (GAD-7) at 24 weeks.

17%

PETRUSHKA Group

Discontinued at 8 wks

27%

Usual Care

Discontinued at 8 wks

0.62

Adjusted RR

95% CI: 0.44–0.88

That's a 38% relative risk reduction in all-cause discontinuation—a clinically meaningful difference. When the researchers looked specifically at discontinuation due to adverse events, the PETRUSHKA group also came out ahead: 9% versus 16% (adjusted RR 0.59, p = .04). This suggests the tool was helping match patients to medications they could actually tolerate.

The Longer View: 24-Week Outcomes

At 24 weeks, participants in the PETRUSHKA group had lower PHQ-9 scores (mean 7.1 vs 9.2, adjusted difference −1.92 points, p < .001) and lower GAD-7 scores (mean 4.6 vs 5.8, adjusted difference −1.39 points, p = .002). A roughly 2-point difference on the PHQ-9 might not sound dramatic, but in a population where the baseline mean was 16.6, a drop to 7.1 puts the average PETRUSHKA patient near the remission threshold of 5, while the usual care group averaged closer to mild-moderate symptom persistence.

Clinical context: A PHQ-9 score of 5–9 corresponds to mild depressive symptoms. Moving a patient from 9.2 to 7.1 represents a meaningful shift in day-to-day functioning—better sleep, more energy, improved concentration, and greater engagement with life.

What Does the Tool Actually Do?

PETRUSHKA integrates clinical variables (symptom profile, comorbidities, prior treatment history) and demographic factors with patient preferences—for example, whether a patient is more concerned about weight gain, sexual side effects, or sedation. The tool then generates a personalized antidepressant recommendation based on the available evidence from network meta-analyses and individual patient data.

This is not pharmacogenomic testing, which remains controversial in psychiatry and is not yet recommended as standard practice by most guidelines. Instead, PETRUSHKA works with the clinical information you're already gathering in a thorough intake. Think of it as a structured framework that synthesizes evidence in a way that's hard to do reliably in your head during a 20-minute visit.

Limitations Worth Noting

The authors themselves flag two significant concerns. First, this was not a double-blind trial—clinicians and patients knew which group they were in, which could have introduced expectation effects. If a patient knows their antidepressant was "personalized" for them, that may increase adherence through a placebo-adjacent mechanism. That's not necessarily a bad thing in real-world practice (whatever keeps patients on effective treatment is welcome), but it tempers the strength of the efficacy signal.

Second, there was a substantial amount of missing data, particularly at the 24-week follow-up, where only 129 participants per group were available for analysis out of the original 493. When nearly half your sample is missing at a key time point, the results need to be interpreted cautiously.

Why This Matters for NP Practice

Nurse practitioners prescribe a large and growing share of antidepressants in the United States, particularly in primary care and psychiatric-mental health settings. Many of us work in environments where we don't have the luxury of a consulting psychiatrist down the hall, and our patients are often dealing with comorbid anxiety, chronic pain, insomnia, and other factors that make antidepressant selection genuinely complex.

The PETRUSHKA trial doesn't solve the antidepressant selection puzzle entirely, but it validates an important principle: structured decision-making that integrates both evidence and patient preferences can outperform clinical intuition alone. That's not a knock on clinical experience—it's a recognition that the sheer volume of evidence across dozens of antidepressants and hundreds of patient variables exceeds what any individual clinician can synthesize in real time.

Bottom Line for NPs

1. The core finding is about adherence, not just efficacy. Patients who received a personalized recommendation were significantly more likely to still be taking their medication at 8 weeks. In a condition where premature discontinuation is one of the biggest barriers to successful treatment, this matters enormously.

2. Patient preferences are part of the equation. The tool explicitly incorporates what side effects patients are most concerned about. This aligns with the shared decision-making model that NPs are already trained to use—the study just provides a structured framework to make those conversations more systematic.

3. Watch this space. The PETRUSHKA tool isn't widely available yet, but the broader movement toward clinical decision-support systems in mental health is accelerating. Familiarize yourself with the concept, and look for future studies that replicate these findings with double-blind designs and better retention.

4. Your clinical judgment still matters. Decision-support tools augment your expertise; they don't replace it. You still know your patient's full story, their social context, their insurance formulary, and the nuances that no algorithm captures.

Reference

Cipriani A, Fernandes KBP, Mulsant BH, et al. A decision-support system to personalize antidepressant treatment in major depressive disorder: a randomized clinical trial. JAMA. Published online March 4, 2026. doi:10.1001/jama.2026.1327

AntidepressantsMajor Depressive DisorderClinical Decision SupportEvidence-Based PracticeMental HealthNP PrescribingShared Decision-Making

Disclosure: This post is for educational purposes only and does not constitute medical advice. The author has no financial relationship with the developers of the PETRUSHKA tool. As always, clinical decisions should be based on the full context of each individual patient encounter.